In the Margins
Valeant Pharmaceuticals has named Mason Morfit, a partner at activist hedge fund ValueAct Capital, to its board of directors. Morfit previously served on the embattled specialty drugmaker's board from 2007 to 2014; ValueAct is one of Valeant's largest shareholders. Read the original story from Forbes.
Most Read
Columbia Funds is in the process of consolidating governance into a unitary board by moving the seven funds in the Columbia Acorn Trust and Wanger Advisors ...
Guinness Atkinson Funds has added two new independent directors to bump the size of the board back up to six members following the year-end retirement of ...
Securities and Exchange Commission Chairman Gary Gensler’s fast and furious rulemaking era will soon be ending, and it is a good time to take stock of ...
Congress created business development companies in 1980 to support job growth and help emerging companies raise funds. As of 2023, there were 139 BDCs with $312 ...